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ABSTRACT 
INTRODUCTION: SORLA is an intracellular sorting receptor in neurons and a major risk 
factor for Alzheimer disease.  
METHODS: Here, we performed global proteome analyses in the brain of SORLA-deficient 
mice followed by biochemical and histopathological studies to identify novel neuronal 
pathways affected by receptor dysfunction.  
RESULTS: We demonstrate that lack of SORLA results in accumulation of phosphorylated 
synapsins in cortex and hippocampus. We propose an underlying molecular mechanism by 
demonstrating that SORLA interacts with phosphorylated synapsins through 14-3-3 adaptor 
proteins to deliver synapsins to calpain-mediated proteolytic degradation.  
DISCUSSION: Our results suggest a novel function for SORLA in control of synapsin 
degradation, potentially impacting on synaptic vesicle endo-/exocytosis.  
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1. BACKGROUND 
Sorting-related receptor with A-type repeats (SORLA, also known as LR11) is a member of 
the VPS10P domain receptor gene family, a unique class of type-1 membrane proteins 
expressed in the mammalian nervous system [1,2]. Initially, these orphan receptors were 
recognized by their structural similarity to the vacuolar protein sorting 10 protein (VPS10P), a 
trafficking receptor in yeast that sorts target proteins between Golgi and endosomal 
compartments [3]. However, recently, VPS10P domain receptors emerged as central 
regulators of neuronal viability and function implicated in many diseases of the nervous 
system including frontotemporal lobar degeneration [4], Alzheimer disease (AD) [5,6], and 
bipolar disorders [7].  
  SORLA is best known for its activity as sorting receptor for the amyloid 
precursor protein (APP), the main etiologic agent in AD. According to current concepts, 
SORLA inhibits trafficking of APP into cellular compartments where secretases reside, 
thereby reducing the extent of proteolytic breakdown of this precursor into neurotoxic 
amyloid-β peptides. Based on cumulative evidence from studies in cultured cells [5,8,9] in 
animal models [2,10] and in humans [6], SORLA is now considered a major risk factor for the 
sporadic form of AD (reviewed in [11]).  
  Although its contribution to amyloidogenic processes is well appreciated, there 
are reasons to believe that the function of SORLA in the nervous system may not be restricted 
to the control of APP transport and processing. Thus, transcription of Sorl1 (the gene 
encoding SORLA) in neurons is strongly induced by brain-derived neurotrophic factor 
(BDNF), implicating this receptor in neurotrophin-dependent pathways [12].  
  To elucidate hitherto unknown functions for SORLA in the nervous system, we 
used an unbiased proteomics approach to compare the brain proteome of SORLA-deficient 
and control mice. Our studies uncovered up-regulation of several phosphorylated (active) 
forms of synapsin 1 and 2 as a consequence of receptor dysfunction. Using biochemical, and 
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histopathological studies, we show that SORLA physically interacts with phospho-synapsins 
and promotes the turnover of these synaptic vesicle (SV) -associated proteins by the protease 
calpain. Our results suggest a novel function for SORLA as modulator of neuronal endo-
/exocytosis. 
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2. RESULTS 
 
2.1 Proteins related to synaptic endo-/exocytosis are altered in the brain of SORLA-
deficient mice. 
We used a two-dimensional polyacrylamid gel electrophoresis (2D-PAGE) approach to 
compare the cortical proteome of one month old SORLA-deficient and control mice. 2D-
PAGE analysis documented 94 significantly altered protein spots in Sorl1-/- compared to 
Sorl1+/+ cortices (Student´s t-test, p<0.05; n=6 biological replicates). Subsequent analysis by 
mass spectrometry revealed the identity of 53 of these spots (Suppl. table 1A). A 
representative gel image of mouse cortex is shown in Suppl. Fig. 1. Enrichment analysis of 
the dataset compared to the whole mouse genome dataset or to a dataset of murine brain 
proteins present in 2D-PAGE [13] identified the gene ontology term “synaptic transmission” -
among other functions- as being significantly enriched in this set of altered proteins 
(p=6.57*10-6 and p=2.20*10-3, respectively). The full result of the enrichment analysis is 
shown in Suppl. Fig. 2. 
  We also performed 2D-PAGE analysis on hippocampal extracts. As in cortex, 
we found predominant alterations in proteins related to synaptic endo-/exocytosis. Altogether, 
90 protein spots were significantly altered in Sorl1-/- compared to Sorl1+/+ hippocampi 
(Student´s t-test, p<0.05; n=6 biological replicates). Of these, 58 spots were identified by 
mass spectrometry (Suppl. table 1B). Analysis revealed enrichment of the gene ontology term 
“transmission of nerve impulse” when compared to the whole mouse genome dataset or to the 
dataset of murine brain proteins in 2D-PAGE [13] (p=6.00*10-4 and p=7.30* 10-3, 
respectively, Suppl. Fig. 2). 
  When comparing our two datasets, we identified two protein families that were 
changed in expression in both, hippocampus and cortex, of Sorl1-/- mice, indicating a more 
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direct functional connection to SORLA. These two protein families were synapsins and 14-3-
3 adaptor proteins, both of which are related to synaptic endo-/exocytosis. 
 
2.2 Phosphorylated synapsins accumulate in the brain of SORLA-deficient mice. 
Several protein spots representing modified forms of synapsins 1 and 2 were significantly 
increased in abundance in cortex and hippocampus of Sorl1-/- animals (Suppl. table1; Fig. 
1A). Quantification of the respective spot volumes documented an approximate ratio of 1.5 to 
1.8 in cortex of receptor-deficient compared to control animals (Fig. 1B; p<0.05). Similar 
increases were seen for synapsin 1 (ratio 1.7; p=0.01) and synapsin 2 (ratio 1.3; p=0.02) in 
hippocampus (Suppl. table 1B). 
  Synapsins are phospho-proteins with eight phosphorylation sites functionally 
characterized so far. Typically, phosphorylation induces mobilization of SV that are 
sequestered by synapsins otherwise (reviewed in [14]). Because accumulation of synapsins 
was seen for multiple iso-spots in our 2-D gels, indicative of alternative post-translational 
modification, we tested the phosphorylation status of these synapsin isoforms using NanoLC-
ESI-MS/MS mass spectrometry. Mass spectrometry revealed that all isoforms of synapsin 1 
and 2 accumulating in Sorl1-/- cortex were phosphorylated (Fig. 1B, Suppl. table 2). In most 
cases, synapsins were phosphorylated at site 1 (Ser9 in synapsin 1, Ser10 in synapsin 2), a site 
phosphorylated upon depolarization following Ca2+ influx. Other identified phosphorylations 
encompassed sites 4, 5, 6, and 7 [14]. Thus, out of eight functionally characterized 
phosphorylation sites in synapsins, six were present in the protein iso-spots accumulating in 
the SORLA-deficient cortex. Additional phosphorylations, which had been identified but not 
functionally characterized thus far (http://www.uniprot.org/), were also present in the 
accumulating synapsin 1 and 2 iso-spots (Fig. 1B, Suppl. table 2).  
  To substantiate the accumulation of phosphorylated (active) forms of synapsin 
1 and 2 in receptor-deficient brains, we analyzed SORLA-deficient mouse cortices by 2D-
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Western blotting applying antibodies that specifically recognize synapsins phosphorylated at 
site 1, site 4, or site 6. In line with our proteome data (Fig. 1B), synapsin 1 phosphorylated at 
sites 1, 4, and 6, as well as synapsin 2 phosphorylated at site 1 were significantly increased in 
abundance in mutant mice (Fig. 2; n=4-6, unpaired Student’s t-test). Taken together, 
accumulation of multi-phosphorylated forms of synapsin 1 and 2 was identified in the Sorl1-/- 
brain, indicating a status of chronic activation of synapsins 1 and 2 as a consequence of 
SORLA deficiency. 
 
2.3 SORLA interacts with synapsin via 14-3-3-adaptor proteins  
Next to synapsins, 2D-PAGE proteome analysis also uncovered significant changes in 
expression levels of 14-3-3 proteins that were reduced in both cortex and hippocampus of 
SORLA-deficient as compared to control mice (Suppl. table 1). For cortex, the spot volume 
ratio Sorl1-/-/Sorl1+/+ for 14-3-3γ was 0.83 (p=0.024). For hippocampus, the spot volume 
ratios for 14-3-3α/β, 14-3-3γ, and 14-3-3ζ/δ  were 0.879 (p=0.01), 0.798 (p=0.04) and 0.772 
(p=0.01), respectively. 14-3-3s are abundant brain proteins that bind to motifs in target 
proteins characterized by phosphorylated serine or threonine residues. 14-3-3 proteins are 
proposed to act as scaffold enabling close proximity of heterologous proteins simultaneously 
bound by 14-3-3 dimers (reviewed in [15]).  
  Using in silico analysis, we identified putative 14-3-3 binding sites in synapsin 
1 (Ser666), in synapsin 2 (Ser546), and in the cytoplasmic tail of SORLA (Ser2168). 
Phosphorylation of SORLA in vivo was described before [16–18]. Our phosphorylation 
analysis further detected phosphorylation of synapsin 1 and 2 at the putative 14-3-3 binding 
sites (Ser666 and Ser546) in mouse cortex, a prerequisite for 14-3-3 binding to these sites 
(Fig. 1B). Together, this raises the possibility of phospho-SORLA to interact with phospho-
synapsins via 14-3-3 adaptors. In support of this hypothesis, the ability of SORLA, synapsin, 
and 14-3-3 to form a complex was confirmed by co-immunoprecipitation (coIP) of the 
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endogenous proteins from mouse cortical extracts using antibodies directed against SORLA 
(Fig. 3A, lane 4) or synapsin (Fig. 3A, lane 7). Because 14-3-3 binding sites are phospho-
motifs, we also tested whether the interaction between SORLA, synapsin, and 14-3-3 was 
sensitive to phosphorylation. To do so, we repeated the coIP experiments using cortical 
lysates dephosphorylated by alkaline phosphatase treatment. The efficiency of coIP of 
SORLA, synapsin, and 14-3-3 from dephosphorylated cortical lysates was reduced 
significantly as compared to untreated samples using both anti-SORLA (Fig. 3A, lane 5) and 
anti-synapsin IgG (Fig. 3A, lane 8). To provide a direct proof for a 14-3-3-dependent 
interaction of SORLA and synapsin, we carried out coIP experiments in the presence of 14-3-
3-specific antisera that block protein interactions. Under these conditions, coIP of SORLA, 
synapsin, and 14-3-3 was strongly impaired (Fig. 3A; lanes 6 and 9). Statistical analysis of 
replicate coIP experiments substantiated the significance of these findings (Fig. 3B-D, n=3-5, 
unpaired Student´t-test). Immunoprecipitation of SORLA and synapsin was also seen with 
three different 14-3-3 binding motif-specific antibodies, confirming the presence of 14-3-3 
interaction sites in either of the proteins (or in both) (Fig. 3E, lanes 2-4). As these binding 
motif-specific antibodies only detect corresponding motifs if phosphorylated, coIP of SORLA 
and synapsin with these antibodies from brain documents phosphorylation of these sites in 
either of the proteins (or in both).  
 
2.4 SORLA regulates synapsin expression through calpain activity 
Since abundance of synapsin 1 and 2 was increased by SORLA deficiency, we wondered 
whether the opposite was true when the receptor was overexpressed. Thus, we analyzed 
lysates of the neuroblastoma cell line SH-SY5Y stably overexpressing SORLA (SY5Y-S) [5]. 
Synapsin levels were substantially reduced in SY5Y-S compared to parental SY5Y cells (Fig. 
4A; lanes 1-4).  
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  It has been shown before that turnover of synapsin is controlled by the 
calcium-activated protease calpain [19]. To evaluate whether the SORLA-dependent 
reduction of synapsin levels was mediated by this protease, we generated cell clones from 
SY5Y and SY5Y-S lines stably overexpressing a small hairpin (sh) RNA directed against 
calpain 1. Knock-down of calpain 1 worked equally well in both cell lines (Fig. 4B, Suppl. 
Fig.4A). Intriguingly, the ability of SORLA to down-regulate synapsin levels was lost when 
calpain 1 expression was reduced in SY5Y-S (Fig. 4A, lanes 5-8; Fig. 4C). Recruitment of 
calpain into a complex composed of SORLA and synapsin was substantiated by coIP 
experiments from mouse cortical extracts using antibodies directed against calpain 1 or 
calpain 2. Both primary antisera co-immunoprecipitated endogenous SORLA and synapsin, 
however, calpain 1 showed a stronger potential to co-immunoprecipitate SORLA as compared 
to calpain2 (Fig. 3E, lanes 5 and 6). So far, our studies provided evidence for the ability of 
SORLA to regulate the levels of expression and the phosphorylation status of synapsin 1 and 
2 in cell lines and in the murine brain. The underlying mechanism possibly involves calpain-
dependent turnover of this synaptic vesicle protein.  
 
2.5 SORLA co-localizes with 14-3-3 and synapsin at synapses 
Based on the ability of SORLA to co-immunoprecipitate synapsins and 14-3-3 (Fig. 3), we 
reasoned that SORLA, which so far was described to reside mostly in the neuronal cell soma, 
also localizes, at least in part, to the pre-synaptic area. Co-localization of SORLA, synapsin, 
and 14-3-3 in synaptic structures was substantiated by immunocytochemistry of primary 
mouse neurons (Fig. 5A-D) and by sub-cellular fractionation (Suppl. Fig. 3). Also, co-
localization of SORLA and synapsin with calpain 1 in synaptic structures of these cells was 
seen (Fig. E-H). The close interaction of SORLA with synapsin, and SORLA with 14-3-3 
protein in primary neurons was confirmed by proximity ligation assay, a PCR-based detection 
assay to demonstrate the proximity of two target proteins (Olink Bioscience; 
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www.olink.com). Close proximity of SORLA with 14-3-3 (Fig. 5I) or of SORLA with 
synapsin (Fig. 5J) was readily seen in primary mouse neurons. Lastly, close proximity of 
SORLA and synapsin within the range of 30 nm in primary neurons was also documented by 
STORM superresolution microscopy (Fig. 5K). 
 
  Collectively, our data from large-scale proteomics to cell biology studies all 
support a model whereby SORLA regulates the functional expression of phospho-synapsin 
through delivery to calpain-mediated degradation (Fig. 6).  
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3. DISCUSSION 
 
Global proteome screens identified expression changes in synapsins as the most prominent 
and consistent feature of cortex and hippocampus proteomes in SORLA-deficient mice. 
Additional experimentation validated these results and revealed that phosphorylated forms of 
synapsin accumulated in SORLA-deficient mice (Fig. 1). Synapsins are encoded by three 
genes in the mammalian genome (Synapsin I, II and III) [20]. Among other functions, 
synapsins are proposed to tether small SV to the actin cytoskeleton, regulating the number of 
vesicles in nerve termini available for release [21]. Upon phosphorylation, synapsins 
dissociate from the cytoskeleton enabling vesicle movement [21]. In line with this model, 
SORLA-dependent control of phospho-synapsin levels in nerve termini may determine the 
distribution of SV between reserve pool and readily releasable pool, rendering this receptor a 
facilitator of neurotransmission and memory consolidation. This way, SORLA deficiency 
may contribute to synaptic dysfunction, a hallmark of AD pathology. Future studies should 
address this potential SORLA-dependent synaptic mechanism in more detail. 
  The ability of SORLA to control functional expression of synapsins is further 
supported by our studies in SH-SY5Y cells wherein overexpression of the receptor resulted in 
decreased levels of the proteins (Fig. 4). Obviously, SH-SY5Y cells lack certain features of 
neurons such as synapses. Thus, functional expression of synaptic vesicle proteins may not 
necessarily be regulated by the exact same mechanisms as in the brain (such as 
phosphorylation). Still, the ability of SORLA to affect synapsin expression in a calpain 1-
dependent mechanism in this cell line argues for a regulatory role of this receptor in synapsin 
bioavailabity in vivo. 
  Our data further suggests that SORLA binds synapsins via 14-3-3 adaptor 
proteins, although we cannot exclude the possibility that additional proteins are involved in 
complex formation. 14-3-3 proteins are dimeric adaptors that bind to phospho-motifs in 
numerous target proteins including synapsins [22,23]. They are enriched in synaptic 
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compartments [24]. In chromaffin cells, blockade of 14-3-3 proteins by antibodies reduces 
neurotransmitter release [25,26] whereas deficiency in Drosophila causes impairment of 
synaptic transmission at the neuromuscular junction [27]. Because 14-3-3s might promote 
interaction of SORLA with synapsin in a phosphorylation-dependent manner, we propose the 
existence of a tripartite complex that regulates phosphorylation-dependent degradation of 
synapsins. Based on our data, complex formation identifies phospho-synapsin molecules 
destined for calpain-mediated degradation, a major pathway for control of synapsin turnover 
[19]. Importantly, shRNA-mediated knockdown of calpain in SH-SY5Y cells levitated the 
effect of SORLA overexpression on synapsin levels (Fig. 4). 
  As well as identifying a role for SORLA in control of functional expression of 
synapsins, our studies also suggest an intriguing link between receptor activity and 
neurotrophin signaling. Thus, previous data identified BDNF as a potent inducer of Sorl1 
gene transcription in neurons suggesting an interesting yet poorly understood role for SORLA 
as downstream effector of BDNF action regulating Aβ production as one immediate 
consequence [12]. In addition, it was reported that SORLA not only impacts on APP 
processing downstream of BDNF, but also boosts BDNF/TrkB signaling by strengthening 
TrkB transportation along neurites [28]. BDNF regulates synaptic plasticity [29] and acute 
treatment with BDNF potentiates excitatory synaptic transmission in brain slices and in 
neurons in vivo [30–32]. These short-term effects of BDNF on synaptic transmission are 
initiated upon binding of BDNF to its receptor TrkB, and by subsequent activation of several 
signaling pathways including ERK [33]. Among other downstream effects, synapsin 
phosphorylation is a well-documented consequence of BDNF/TrkB signaling through ERK 
[34]. It causes strengthening of neurotransmitter release, a short-term mode of action how 
BDNF participates in memory consolidation. Interestingly, more recently a study using 
induced pluripotent stem cells (iPSC) from patients documented, that risk haplotypes in Sorl1 
respond less to BDNF than protective haplotypes. In detail, it was reported that BDNF could 
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only induce Sorl1 expression in iPSC that carried at least one protective receptor haplotype 
[35]. The authors also reported that, in line with previous work [36], BDNF only reduced Aβ 
production in cells capable of inducing SORLA, highlighting the importance of the interplay 
between SORLA and BDNF in the disease situation. The relevance of the here described 
SORLA-dependent control of synapsins should be explored in the context of BDNF-
dependent synaptic modulation in AD in future studies.  
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4. MATERIAL AND METHODS 
 
4.1 Materials 
Antibodies directed against synapsins (Fig. 2, 3, 4; Suppl. Fig. 3); synapsin 1 (Synapsin1XP; 
Fig. 5), phospho-synapsin–site 1 (Fig. 2), 14-3-3γ (Fig. 3A), 14-3-3 binding motifs (Fig. 3D), 
calpain-1/-2 (Fig. 4, 5), and PSD-95 (Suppl. Fig. 3) were purchased from Cell Signaling 
Technology. Antibodies directed against synapsin 1 phosphorylated at sites 4 and 6 were 
purchased from Abcam (Fig. 1). Antibodies directed against synapsins phosphorylated at sites 
1, 4, and 6 correspond to anti-phospho-synapsin (Ser9), anti-phospho-synapsin 1 (Ser62), and 
anti-phospho-synapsin 1 (Ser549), respectively, according to the originally identified 
phosphorylation sites in the rat [14]. Antibodies directed against 14-3-3 binding motifs correspond to motif 1 (Arg/Lys and Ser at positions -3 and -2, phospho-Ser at position 0, and Pro at position +2; “motif a”, polyclonal antibody; “motif b, monoclonal antibody) and motif 2 (Phospho-(Ser) Arg-X-Tyr/Phe-X-pSer; “motif c”), respectively [37]. 
Additional antisera used include anti-14-3-3 pan (Fig. 3; US Biological), anti-tubulin 
(Calbiochem), and anti-synapsin (used for IP; SYnaptic SYstems). Rabbit N-terminal anti-
SORLA serum (epitope: amino acids 54-2107 of SORLA) was produced in-house and 
characterized in previous studies [38,39]. The calpain 1 shRNA plasmid used for stable 
calpain knock-down in SH-SY5Y cells was purchased from Santa Cruz. 
. 
4.2 Animal and cell experimentation 
The generation of Sorl1-/- mice by targeted gene disruption has been reported [5]. Animals 
were kept on an inbred Balb/c genetic background and compared to age- and gender-matched 
Balb/c wild-type controls. All animal experimentation was performed in accordance with 
guidelines of animal welfare after approval by local ethics committees. Primary cortical neurons were prepared from newborn Balb/c mice of either sex at postnatal day 1. 
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Cortices were dissociated in papain (1 hour at 37°C) and cultured on poly-D-lysine/collagen coated culture dishes. The neurons were cultured for 4-5 days in Neurobasal-A medium (Gibco) including B27 supplement (Sigma), and GlutaMAX (Invitrogen) as previously described [5]. 
 
 Proteome analyses 
Cortices and hippocampi were prepared from 1-month old SORLA-deficient and control male 
mice (n=6 per genotype). Proteins were extracted from shock-frozen tissue according to 
published protocols [40,41]. Protein extracts were separated using the 2D-PAGE technique as 
described [41]. The gel format was 40 cm (isoelectric focusing) x 30 cm (SDS-PAGE) x 0.9 
mm (gel width). Two dimensional protein patterns were obtained by silver staining of gels 
and spot patterns were evaluated by Delta2D imaging software (version 4.0, Decodon).  
  For protein identification, 1.2 mg of the respective protein extracts were 
separated by 2D-PAGE and stained using a mass spectrometry (MS) compatible silver 
staining protocol [42]. Protein spots of interest were excised from 2D gels and subjected to in-
gel tryptic digestion. Peptides were analyzed by an ESI-tandem -MS/MS on a LCQ Deca XP 
ion trap instrument with Nano-LC (Thermo Scientific). Mass spectra were analyzed using 
MASCOT software (version 2.2) automatically searching the SwissProt database (version 
51.8, 513877 sequences). MS/MS ion search was performed with the following set of 
parameters: (i) taxonomy: Mus, (ii) proteolytic enzyme: trypsin, (iii) maximum of accepted 
missed cleavages: 1, (iv) mass value: monoisotopic, (v) peptide mass tolerance 0.8 Da, (vi) 
fragment mass tolerance: 0.8 Da, and (vii) variable modifications: oxidation of methionine 
and acrylamide adducts (propionamide) on cysteine. No fixed modifications were considered. 
Only proteins with scores corresponding to p<0.05, with at least two independent peptides 
identified were considered. The cut-off score for individual peptides was equivalent to p<0.05 
for each peptide as calculated by MASCOT respectively.  
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With current technologies, the analysis of the whole mouse brain proteome is not possible 
[43]. Every available method can only detect a small part of the complex proteome present in 
eukaryotic tissues. A list of proteins that are covered by our methodological approach was 
published previously [13]. This dataset was also used as reference for enrichment analysis. 
 
4.3 Determination of phosphorylation sites by mass spectrometry 
LC-MS measurements were performed as described [44]. In brief, excised protein spots were 
washed with 50% (v/v) acetonitrile in 50 mM ammonium bicarbonate, shrunk by dehydration 
in acetonitrile, and dried in a vacuum centrifuge. The dried gel spots were incubated with 
either 50 ng trypsin (Promega), or 110 ng chymotrypsin (Roche Diagnostics), or 60 ng Asp-N 
(Roche Diagnostics) in 10 µL of 50 mM ammonium bicarbonate at 25 °C overnight. To 
extract the peptides, 10µL of 0.5% (v/v) trifluoroacetic acid in acetonitrile was added and the 
separated liquid was dried under vacuum. For MS analysis, the samples were reconstituted in 
6 µL of 0.1% trifluoroacetic acid in acetonitrile/water (5:95). Peptides were analyzed by a 
reversed-phase capillary liquid chromatography system (Eksigent NanoLC Ultra, Axel 
Semrau) connected to an LTQ Orbitrap XL mass spectrometer (Thermo Scientific). LC 
separations were performed on a capillary column (PepMap100, C18, 3 μm, 100 Å, 250 mm × 
75 μm i.d., Dionex) at an eluent flow rate of 200 nL/min using a linear gradient of 3–25% B 
in 75 min with further increase to 50% B at 80 min. Mobile phase A contained 0.1% formic 
acid in water, and mobile phase B contained 0.1% formic acid in acetonitrile. Mass spectra 
were acquired in a data-dependent mode with one MS survey scan (with a resolution of 
60,000) in the Orbitrap and MS/MS scans of the four most intense precursor ions in the linear 
trap quadrupole. The processed MS/MS data and MASCOT server (version 2.2.2, Matrix 
Science Ltd, London) were used to search in-house against the SwissProt database (Version 
2012_12, Taxonomy: mouse, 50697 sequences, 24398386 residues). The mass tolerance of 
precursor and sequence ions was set to 15 ppm and 0.35 Da, respectively. The search includes 
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variable modifications of cysteine with acrylamide, methionine oxidation, and 
phosphorylation of serine, threonine, or tyrosine. The maximum of 2, 5, and 2 missed 
cleavages was allowed for tryptic, chymotryptic, and Asp-N peptides, respectively. To 
identify phosphorylated synapsin peptides, probability-based scoring (MASCOT score) was 
used. In addition, tandem mass spectra of phosphopeptides were manually verified and 
compared with the theoretical fragment ions of synapsin. 
 
4.4 Immunoprecipitation  
Immunoprecipitation from mouse cortical lysates was carried out using the co-
Immunoprecipitation Kit (Pierce) according to manufacturer’s instructions. For antibody-
based interference with co-immunoprecipitation, anti-14-3-3 pan IgG (10 ng/µl) was added to 
the samples and co-incubated at 37°C for 1h. Control samples without further treatment were 
also incubated at 37°C for 1 hour. Western blot analysis was conducted using standard 
protocols and blots were developed with Super Signal West Femto Chemiluminescent 
Substrate (Pierce). For densitometric analysis, signal intensities were quantified using 
Advanced Image Data Analyzer (AIDA) software (Raytest) version 3.51. )  
 
4.5 Proximity ligation assay 
Proximity ligation assay (PLA) is a PCR based detection assay to demonstrate close proximity 
of two target proteins (Olink Bioscience; www.olink.com). PLA was performed according to 
manufacturer’s instruction (Duolink II Brightfield User Manual) on primary cortical neurons 
from wild type mice with the primary antibodies anti-SORLA, anti-Synapsin1XP (Cell 
Signaling), and anti-14-3-3 gamma (Cell Signaling), followed by incubation with secondary 
antibodies conjugated to oligonucleotides, which hybridize to subsequently added circle-
forming oligonucleotides and prime a rolling circle amplification, if the antigens are located 
within proximity of 40 nm or less.  
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4.6 Stochastic Optical Reconstruction Microscopy (STORM) 
For STORM superresolution microscopy primary neurons were visualized using a Nikon 
Eclipse Ti-E STORM microscope with Apo TIRF 100X 1.49 Oil objective, EM-CCD Camera 
iXon DU897 (Andor), inbuilt Perfect Focus System, and inbuilt drift control. SORLA and 
synapsin were stained using secondary antibodies either labeled with Atto 488 or Alexa 647 
fluorophores. As buffer for imaging TRIS buffered saline (50 mM, pH=8) including 100 mM 
ethanolamine (MEA) and glucose oxidase (0.5 mg/ml) as well as catalase (40 µg/ml) together 
with 10% glucose was used. 
    
Statistical analyses 
For proteomic analyses datasets were analyzed using a paired two-tailed Student’s t-test as 
SORLA-deficient and control samples were always handled in pairs starting with protein 
extraction until after completion of 2-D gel runs. Only spot volume ratios ≥ 20% were 
considered (n = 6 biological replicates, significance threshold p ≤ 0.05). Normality of data 
was evaluated using Kolmogorov-Smirnov testing [40].   
Enrichment analysis based on gene ontology terms was conducted by applying the following 
settings provided by WebGestalt: Hypergeometric test; p≤0.05; more than 2 proteins per 
category. The set of proteins altered by SORLA deficiency was compared to the mouse 
genome dataset provided by WebGestalt or to a dataset of proteins present on 2-D gels of 
brain tissue as reference, respectively [13].  
For densitometric quantifications of Western blots, statistical tests applied and numbers of 
biological replicates (n) are given in the respective figure legends. Box plots depict medians 
as well as lower quartile, upper quartile, and sample maxima.  
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FIGURES 
 
Figure 1. SORLA deficiency results in accumulation of synapsin 1 and 2 in the cortex.  
(A) Segments of large two-dimensional polyacrylamide gels of cortical proteins from 
Sorl1+/+ and Sorl1-/- mice stained with silver nitrate are shown. An exemplary complete gel is 
shown in Suppl. Fig. 1. Red circles highlight protein spots corresponding to isoforms of 
synapsin 1a, 1b, and 2a that are significantly altered in SORLA-deficient as compared to wild 
type cortices (Spot ID a - g). (B) List of protein iso-spots of synapsin 1a, 1b, and 2a that are 
significantly altered in the cortex of Sorl1-/- compared to control mice (n=6 per genotype; 
paired two-tailed Student’s t-test, p<0.05). The phosphorylation sites identified for the 
respective iso-spots by NanoLC-ESI-MS/MS mass spectrometry are also given. Numbers in 
brackets refer to the numbering of synapsin phosphorylation sites 1 through 8 as described in 
[14]. A slash between two modification sites indicates that an unambiguous assignment of 
phosphorylation site was not possible. 
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Figure 2. Increased phosphorylation of isoforms of synapsin 1 and 2 in Sorl1-/- mice. 
(A) Small two-dimensional polyacrylamide gels of cortical proteins from Sorl1+/+ and Sorl1-/- 
cortices were subjected to Western blot analysis using antibodies specific for phospho-
synapsins 1 and 2 isoforms phosphorylated at p-site 1, p-site 4, or p-site 6. (B) Densitometric 
quantifications of Western blots as exemplified in (A) document significant accumulation of 
synapsin 1 phosphorylated at site 1, site 4, and site 6, as well as synapsin 2a phosphorylated at 
site 1 in Sorl1-/- cortex as compared to controls (n=4-6, unpaired Student’s t-test). 
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Figure 3. Phosphorylation-dependent interaction of SORLA with synapsin and 14-3-3. 
(A) Immunoprecipitation of SORLA (IP SORLA; lanes 4 - 6) or synapsin (IP synapsin; lanes 
7 - 10) from total mouse cortical lysates either untreated (w/o), treated with alkaline 
phosphatase (dephos.), or incubated with pan-14-3-3 antibodies (Ab). Co-
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immunoprecipitation of the indicated proteins was confirmed by Western blot analyses. 
Efficient co-immunoprecipitation of SORLA, synapsin, and 14-3-3 is seen in untreated tissues 
(lanes 4 and 7), but to a lesser extent from dephosphorylated (lanes 5 and 8) or from anti-14-
3-3 IgG treated samples (lanes 6 and 9). Lanes 1 - 3 depict the presence of SORLA, synapsin, 
and 14-3-3 in cortical lysates prior to immunoprecipitation. Lane 10 indicates lack of co-
immunoprecipitation of SORLA, synapsin, and 14-3-3 in the absence of primary antibody. (B 
- D) Quantification of co-immunoprecipitation results as exemplified in panel A by 
densitometric scanning of Western blots documents significantly impaired coIP of 14-3-3 (B), 
synapsin (C), and SORLA (D) in dephosphorylated (dephos.) or 14-3-3 antibody-treated (Ab.) 
conditions as compared to untreated controls (w/o; set to 100%) (n=3-5, unpaired Student’s t-
test). (E) Co-immunoprecipitation of SORLA and synapsin from total mouse cortical lysates 
using three different antibodies directed against 14-3-3 binding motifs (lanes 2 - 4) or antisera 
directed against calpain 1 (lane 5) or calpain 2 (lane 6). No co-immunoprecipitation was 
observed in conditions lacking primary antibody (lane 7). The presence of SORLA and 
synapsin in the brain lysate prior to immunoprecipitation is shown in lane 1 (Input). 
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Figure 4. SORLA modulates calpain-dependent turnover of synapsin. 
(A) Western blot analysis demonstrates reduced levels of synapsins in SH-SY5Y cells 
overexpressing SORLA (SY5Y-S; lanes 3 - 4) compared to the parental cell line (SY5Y; 
lanes 1 - 2). No difference in synapsin levels between the two cell lines is seen when 
expression of calpain 1 is blocked by a small hairpin (sh) RNA (lanes 5 – 8). Detection of 
tubulin served as loading control. (B) Loss of calpain 1 expression works equally well in 
SY5Y and SY5Y-S cells expressing a shRNA directed against calpain 1 (+ shCalp1) 
compared to the untreated cell lines (mean set at 100%) as determined by replicate Western 
blot analyses (n=5; p=0.008, Mann-Whitney-U). (C) Quantification of synapsin levels in the 
indicated cell lines by densitometric scanning of replicate Western blots. Synapsin levels are 
significantly reduced in untreated SY5Y-S compared with parental cells (mean set at 100%) 
(n=5; p=0.0079, Mann-Whitney-U). In contrast, no difference in synapsin levels is seen when 
cells lack calpain 1 expression (n=5; p=0.1508, Mann-Whitney-U).   
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Figure 5. SORLA colocalizes with synapsin and 14-3-3 at synapses. 
 (A-D) Immunocytochemical detection of SORLA (red), synapsin (blue), and 14-3-3 (green) 
in primary mouse neurons using confocal microscopy.  Co-localization in synaptic structures 
is indicated in the inset to the merged micrograph by arrowheads. Scale bar: 20 µm. (E-H) 
Immunocytochemical detection of SORLA (blue), synapsin (red), and calpain (green) in 
primary mouse neurons using confocal microscopy. Co-localization of all three proteins in 
synaptic structures is indicated in the inset to the merged micrograph by arrowheads. Scale 
bar: 20 µm. (I-K) Proximity ligation assays (PLA) for SORLA and 14-3-3 (I) and for SORLA 
and synapsin (J) are shown. Red dots indicted close proximity of the respective proteins 
(arrowheads). No PLA signal is when omitting the primary antibodies as negative control (K). 
Close proximity of the respective proteins is indicated by red signals. Nuclei are stained with 
DAPI. Scale bar: 5µm. (L) STORM superresolution microscopy for SORLA (red) and 
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synapsin (green) in primary neurons. Arrowheads highlight close interaction of the proteins in 
synaptic structures. Scale bar: 700 nm. 
 
 
Figure 6. Proposed function of SORLA in control of synapsin activity.   
Unphosphorylated synapsin promotes clustering of synaptic vesicles (SV) in the reserve pool 
of the nerve terminus. Upon phosphorylation of synapsin, SV dissociate from this cluster and 
enter the active zone to dock with the presynaptic plasma membrane (step 1). A fusion pore 
opens and neurotransmitters are released into the synaptic cleft (step 2). In the peri-active 
zone, inward budding of the plasma membrane forms new SV that carry p-synapsin (step 3). 
Phosphorylated forms of SORLA and p-synapsin complex via 14-3-3 adapter proteins 
delivering p-synapsin to calpain-dependent degradation associated with synaptic endosomes 
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(step 4). SV not tagged by SORLA are recycled back to the SV cluster (step 5). According to 
this model, loss of SORLA activity results in an increased fraction of vesicles carrying p-
synapsin molecules, thereby causing an overall larger pool of mobilized SV.  
 
